Downregulation of VEGF mRNA expression by triamcinolone acetonide acetate-loaded chitosan derivative nanoparticles in human retinal pigment epithelial cells

Background The purpose of this study was to investigate the downregulation of mRNA expression of vascular endothelial growth factor (VEGF) by triamcinolone acetonide acetate (TAA)-loaded chitosan nanoparticles in human retinal pigment epithelial cells. Methods TAA-loaded deoxycholic acid-modified chitosan (TAA/DA-Chit) nanoparticles were prepared via a self-assembly mechanism, and their morphology and zeta potential were examined by transmission electron microscopy and zeta potential analysis, respectively. DA-Chit and TAA/DA-Chit nanoparticle toxicity was evaluated using a Cell Counting Kit-8 assay. The efficiency of cellular uptake was determined using fluorescein isothiocyanate-labeled DA-Chit nanoparticles, in place of TAA/DA-Chit nanoparticles, assessed by both inverted fluorescence microscopy and flow cytometry. Downregulation of VEGF mRNA expression by TAA/DA-Chit nanoparticles was further investigated by real-time reverse transcription polymerase chain reaction (RT-PCR) assay of the treated human retinal pigment epithelial cells. Results TAA/DA-Chit nanoparticles were prepared with a TAA-loading capacity in the range of 12%–82%, which increased the water solubility of TAA from 0.3 mg/mL to 2.1 mg/mL. These nanoparticles showed oblate shapes 100–550 nm in size in transmission electron microscopic images and had positive zeta potentials. The Cell Counting Kit-8 assay indicated that the DA-Chit and TAA/DA-Chit nanoparticles had no toxicity and low toxicity, respectively, to human retinal pigment epithelial cells. Fluorescein isothiocyanate-labeled DA-Chit nanoparticle uptake by human retinal pigment epithelial cells was confirmed by inverted fluorescence microscopy and flow cytometry. Real-time RT-PCR assay showed that the VEGF mRNA level decreased after incubation of human retinal pigment epithelial cells with TAA/DA-Chit nanoparticles. Conclusion TAA/DA-Chit nanoparticles had a downregulating effect on VEGF mRNA expression in human retinal pigment epithelial cells and low cytotoxicity, which might be beneficial characteristics for the development of future treatment for diabetic retinopathy.

[1]  Xiang Cai,et al.  Ophthalmic drug-loaded N,O-carboxymethyl chitosan hydrogels: synthesis, in vitro and in vivo evaluation , 2010, Acta Pharmacologica Sinica.

[2]  S. Oliver,et al.  Diabetic retinopathy: An update on treatment. , 2010, The American journal of medicine.

[3]  Maria Jose Alonso,et al.  Chitosan-based nanostructures: a delivery platform for ocular therapeutics. , 2010, Advanced drug delivery reviews.

[4]  W. Hennink,et al.  Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans. , 2009, Biomaterials.

[5]  Hyesung Jeon,et al.  Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Changren Zhou,et al.  Polysaccharides-based nanoparticles as drug delivery systems. , 2008, Advanced drug delivery reviews.

[7]  Huibi Xu,et al.  Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. , 2008, International journal of pharmaceutics.

[8]  Xiao-tao Li,et al.  Nanofibrous polyhydroxyalkanoate matrices as cell growth supporting materials. , 2008, Biomaterials.

[9]  Young-Hoon Park,et al.  Effect of a single intraoperative sub‐Tenon injection of triamcinolone acetonide on the progression of diabetic retinopathy and visual outcomes after cataract surgery , 2008, Journal of cataract and refractive surgery.

[10]  Kim Ramasamy,et al.  Diabetic retinopathy: An update , 2008, Indian journal of ophthalmology.

[11]  Zhiquan Li,et al.  Loading and in vitro controlled release of indomethacin using amphiphilic cholesteryl-bearing carboxymethylcellulose derivatives. , 2008, Macromolecular bioscience.

[12]  M. Gillies,et al.  Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas , 2008, Diabetes.

[13]  Jaeryung Oh,et al.  The effect of short-term exposure of triamcinolone acetonide on fibroblasts and retinal pigment epithelial cells. , 2007, Acta ophthalmologica Scandinavica.

[14]  C. H. Park,et al.  Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage. , 2007, Life sciences.

[15]  G. Peyman,et al.  Triamcinolone acetonide in ocular therapeutics. , 2007, Survey of ophthalmology.

[16]  C. H. Park,et al.  Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia , 2007, Neurobiology of Disease.

[17]  Dong Ho Jung,et al.  KIOM-79 inhibits high glucose or AGEs-induced VEGF expression in human retinal pigment epithelial cells. , 2007, Journal of ethnopharmacology.

[18]  Liqun Yang,et al.  Amphiphilic cholesteryl grafted sodium alginate derivative: Synthesis and self-assembly in aqueous solution , 2007 .

[19]  J. Hwang,et al.  N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Ş. Özdek,et al.  Effects of Intravitreal Triamcinolone Injection on Macular Edema and Visual Prognosis in Central Retinal Vein Occlusion , 2006, International Ophthalmology.

[21]  C. Pillai,et al.  Chitosan/oligo L-lactide graft copolymers: Effect of hydrophobic side chains on the physico-chemical properties and biodegradability , 2006 .

[22]  G. Seigel,et al.  Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. , 2006, Investigative ophthalmology & visual science.

[23]  J. Jonas.  Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. , 2005, Acta ophthalmologica Scandinavica.

[24]  J. Jonas,et al.  Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases , 2005, Progress in Retinal and Eye Research.

[25]  M. Sydorova,et al.  Vascular Endothelial Growth Factor Levels in Vitreous and Serum of Patients with either Proliferative Diabetic Retinopathy or Proliferative Vitreoretinopathy , 2005, Ophthalmic Research.

[26]  Y. Tano,et al.  Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. , 2005, Investigative ophthalmology & visual science.

[27]  H. Yamashita,et al.  Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II , 2004, British Journal of Ophthalmology.

[28]  C. Pang,et al.  The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. , 2003, Investigative ophthalmology & visual science.

[29]  H. Yamashita,et al.  Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. , 2003, Ophthalmology.

[30]  K. Yamashiro,et al.  VEGF164 is proinflammatory in the diabetic retina. , 2003, Investigative ophthalmology & visual science.

[31]  M. Matsumura,et al.  Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. , 2002, American journal of ophthalmology.

[32]  R. Pignatello,et al.  Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  P. Campochiaro,et al.  VEGF is major stimulator in model of choroidal neovascularization. , 2000, Investigative ophthalmology & visual science.

[34]  I. Kwon,et al.  Synthesis and the micellar characteristics of poly(ethylene oxide)-deoxycholic acid conjugates , 2000 .

[35]  L. Kagemann,et al.  Regional differences in retinal vascular reactivity. , 1999, Investigative ophthalmology & visual science.

[36]  Abraham Nudelman,et al.  NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. , 1997, The Journal of organic chemistry.

[37]  Y Ikada,et al.  In vitro and in vivo degradation of films of chitin and its deacetylated derivatives. , 1997, Biomaterials.

[38]  H. Dvorak,et al.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.

[39]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[40]  조원호,et al.  Structural determination and interior polarity of self-aggregates prepared from deoxycholic acid-modified chitosan in water , 1998 .